Atropos Healtha company that translates real-world clinical data (RWD) into real-world evidence, has announced a strategic partnership with Ontada, a McKesson business involved in community oncology.
Ontada is connected to the American Oncology Network, a wholly owned subsidiary of McKesson, providing real-time data, insights, and research into ways of treatment in the community.
The collaboration aims to enhance use cases for clinicians, researchers and healthcare leaders to design care protocols, promote precision medicine and create new treatments for oncology.
Atropos Health’s automation tools generate evidence from customer data by installing an operating system for rapid medical evidence on the customer’s internal cloud data environment and Atropos Evidence Network.
Evidence Network members can leverage longitudinal patient data from participating network sources to provide access to identified patient records while maintaining data ownership and security.
Members can also run queries on the RWD of Atropos Evidence Network and run access data for each question that is rated by their actual fitness score.
The collaboration follows Atropos Health’s March announcement of federation nodal edidentification technology.
According to the company, NODAL clarification allows users to fill data gaps in patient longitudinal records from participating ATROPOS evidence network sources.
“There is always a demand for high quality data in oncology,” Brigham Hyde, CEO and co-founder of Atropos Health, said in a statement.
“The Atropos Evidence Network currently includes RWD from Ontada, but it includes benefits across the healthcare ecosystem. For the health system, the oncology multimodal network includes the high quality RWD needed to generate the RWE needed for high quality clinical decisions.”
Bigger trends
February, Emory Healthcare has partnered with Atropos Health to advance its medication prescription decisions and protocols. Emory piloted a program that advances patient care by using Atropos’ platform to enable real-time answers to clinical questions.
The Atropos Evidence Network allows Emory users to perform research on national datasets and local Emory data. Clinicians also use the green button on Atropos to access RWE.
In January, Atropos Health partnered Xcure, an AI-powered healthcare data search company, uses RWE-based insights to support patient care.
The partnership aims to leverage AI, the Atropos Evidence Network and the XCURES platform to develop and deploy approved prognostic and decision support tools to healthcare providers in the healthcare ecosystem.
That same month, Atropos partnered Merck generates RWE, replicates your research, and creates rapid insights and analysis of real-world data.
Merck’s Data Science and RWE team will employ Atropos Health Services such as Geneva Male Green Button, Atropos Evidence Network, Alexandria, Forge, ChatRWD, and more.
In 2024, Atropos was secured Series B funding for $33 million.
Valtruis led the investment round, including new investors McKesson Ventures, Merck Ghi Fund, Cencora Ventures.
Existing Investors Emerson Collective, Blayer Capital and Presidio Venture also participated in the round
Mike Spadafore, Managing Director of Valtruis, has joined the company’s board of directors.
Atropos has also announced the Healthcare Data Analytics Company Arcadia joined the health portfolio that year, giving customers and life science users of Arcadia providers access to Atropos products.
Through the partnership, Arcadia joined the Atropos evidence network. This allowed users to access Atropos’ portfolio of applications to support clinical decision-making in value-based care.
